Clinical Trial: Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07908316) titled 'Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)' on Oct. 27.

Brief Summary: The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.

Study Start Date: Nov. 13

Study Type: INTERVENTIONAL

Condition: Obesity Overweight

Intervention: DRUG: Maridebart cafraglutide

Administered subcutaneously.

Recruitment Status: RECRUITING

Sponsor: Amgen

Disclaimer: C...